Direct access to content

Advanced research

Direct line: +33 1 58 18 69 00


You are here : Homepage > Live > Press

A competitiveness cluster, bioparks, economic development agencies, research centre and businesses: Paris Region will be exhibiting at BIO!

Tuesday, June 7th

After its success at last year's BIO, Paris Region, Europe's number one region for R&D, will once again be taking an active part in the biotechnology sector's leading international event, which is attended by the sector’s most dynamic players. Join us: Hall A, stand 2505 - BIO, Washington DC

BiOWashington.jpg

The Paris Region exhibitors represent the region's excellence in this sector and will all be together in an area of almost 970 sq.ft under the "Medicen Paris Region" banner.

"Paris Region is home to internationally recognised experts and a broad range of complementary businesses, which is what makes the region so attractive! says Denis Tersen, Chief Executive Officer of the Paris Region Economic Development Agency. In recent years Paris Region has created a unique environment conducive to forging partnerships with other clusters in America, Asia and Europe and attracting foreign companies to the region. For these businesses, choosing Paris Region means being certain of finding competent partners and interlocutors, with the added benefit of being geographically close to the market leaders. This climate of trust stimulated investment in 2010 with a large number of French biotech companies floating on the stock market."
This year the competitiveness cluster Medicen Paris Region, the bioparks Genopole and Cancer Campus, the Paris Region and Essonne economic development agencies, and the Paris hospital network AP-HP (Europe's leading Contract Research Organisation) will be joined by eight Paris Region businesses: Aepodia, Ariana Pharma, Harmonic Pharma, Medit, O4CP, Oncodesign, Oroxcell and Texcell.


You can access to the entire companies profiles here.


The Paris Region biotechnology sector is associated with the Medicen Paris Region competitiveness cluster and accounts for around a third of French companies and jobs in the biotech field. In 2010, over €440 million was invested in French biotechnology companies, either through venture capital or the stock market. Twenty-one French biotech companies are publicly listed.


Dates :
Published on June 7, 2011

update June 21, 2011

Send this page

Share :

           Follow me on twitter

Aude COLONNA

Tel. : +33 (0)1 58 18 69 53

Send a message

Documents to download

All publications
  • Testimony of Aurélien LUGARDON

    more

All testimonies

Search a document

Search a document